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Abstract
Background: Acute myeloid leukemia (AML) comprises a group of diseases characterized by the
abnormal development of malignant myeloid cells. Recent studies have demonstrated an important
role for aberrant transcriptional regulation in AML pathophysiology. Although several transcription
factors (TFs) involved in myeloid development and leukemia have been studied extensively and
independently, how these TFs coordinate with others and how their dysregulation perturbs the
genetic circuitry underlying myeloid differentiation is not yet known. We propose an integrated
approach for mammalian genetic network construction by combining the analysis of gene
expression profiling data and the identification of TF binding sites.
Results: We utilized our approach to construct the genetic circuitries operating in normal myeloid
differentiation versus acute promyelocytic leukemia (APL), a subtype of AML. In the normal and
disease networks, we found that multiple transcriptional regulatory cascades converge on the TFs
Rora and Rxra, respectively. Furthermore, the TFs dysregulated in APL participate in a common
regulatory pathway and may perturb the normal network through Fos. Finally, a model of APL
pathogenesis is proposed in which the chimeric TF PML-RARα activates the dysregulation in APL
through six mediator TFs.
Conclusion: This report demonstrates the utility of our approach to construct mammalian genetic
networks, and to obtain new insights regarding regulatory circuitries operating in complex diseases
in humans.

Background

Acute myeloid leukemia (AML) comprises a group of diseases
characterized by abnormal myeloid differentiation and an

accumulation of abnormal myeloid cells in the bone marrow
and peripheral blood. Like other complex diseases in
humans, AML is likely to be caused by disruption or
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dysregulation of multiple regulatory pathways. Recent studies have demonstrated a key role for aberrant transcriptional
regulation in AML pathophysiology. Namely, many lineagespecific transcription factors (TFs), which coordinate normal
myeloid development, are often mutated or altered in genetic
fusions produced by chromosomal translocations [1,2].
Moreover, participants of many of these chimeric proteins are
themselves TFs [3,4]. These TFs may in turn interact with the
normal genetic circuitry involved in myeloid differentiation
and induce downstream events in AML pathogenesis.
Although several chromosomal fusion proteins and myeloid
TFs involved in leukemia have been identified and studied
independently, how each individual TF interacts with others,
and how each regulatory pathway correlates with others,
remains unclear. Such comprehensive delineation of the
genetic networks underlying both normal myeloid differentiation and leukemia is crucial to better understand AML
pathophysiology and to develop improved therapeutic
strategies.
Uncovering genetic networks has been a great challenge in
the post-genomic era. Breakthroughs in experimental methods such as chromatin immunoprecipitation followed by promoter arrays [5] have vastly improved the efficiency of TF
target identification [6,7], but these methods may be applied
to only one TF under one condition in one experiment and,
therefore, are laborious and time consuming. Alternatively,
computational methods seek to solve this problem using a
systems biology approach. A majority of these methods have
utilized analysis of gene expression profiling experiment data
to construct a coexpression network. These approaches usually apply computational algorithms or machine learning
techniques such as analytical methods [8,9], statistical
regression [10], Bayesian networks [11-13], support vector
machine [14], data processing inequality [15] and minimum
description length principle [16]. However, due to the complexity of expression data (that is, the expression of many
genes are measured only at a few data points), it is generally
difficult to identify the dependencies and interactions
between TFs and their target genes accurately. One common
challenge of expression profiling based methods is to distinguish coregulation from coexpression. Namely, genes that are
coherently expressed with a TF are not necessarily directly
regulated by that TF. Therefore, most of these methods have
focused on simpler organisms, such as bacteria or yeast, in
which the number of TF genes is small and the structure of the
regulatory network is simpler.
Another approach to constructing genetic networks is based
on identification of TF binding sites. This approach either
predicts the transcriptional regulators of a set of coexpressed
genes [17,18] or predicts the regulatory targets of TFs using
their binding sites [19,20]. In these methods, a model of TF
binding elements is first built by experimental or computational methods. This model is then used to search for genes
that have matching sites in their non-coding sequence. A net-
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work of transcriptional regulation may be constructed by
identifying targets for each individual TF. The advantage of
this approach over expression based methods is that it identifies direct regulatory targets of a TF. However, its performance is strongly based on the accuracy of the TF binding site
identification. Due to the high false discovery rate of TF binding sites, this approach has primarily been successful in simpler organisms [17,21], and applying this approach to
mammals is still difficult and challenging.
Because each of these approaches has its own advantages and
limitations, recent studies have taken an integrated approach
to combine multiple types of information in order to make
better predictions on regulatory networks. These methods
include combining gene expression data with TF binding site
analysis [22-24], combining chromatin immunoprecipitation
with gene expression data [25-27], and combining chromatin
immunoprecipitation data with regulatory motif discovery
[28]. Although the performance of these integrated
approaches is superior compared to the individual methods,
most of them have been designed and tested only in lower
eukaryotes. Therefore, the accurate identification of genetic
networks in mammals remains a challenging problem.
In this report, we present a novel approach to inferring
genetic networks in mammals by combining gene expression
profiling data and TF binding site analysis. We utilize this
approach to study the genetic networks operating in myeloid
differentiation and to elucidate how this circuitry goes awry in
acute promyelocytic leukemia (APL), a subtype of AML. APL
was chosen because its pathogenesis is likely based on a common mechanism involving transcriptional dysregulation.
Namely, APL is characterized by the presence of a chromosomal fusion protein, PML-RARα [4]. One participant of this
chimeric protein, RARα, is a TF. Therefore, it is feasible that
disruption of RARα function initiates the dysregulatory
events in APL and is thus a good model for predicting the perturbation of genetic networks. Using our analytical
approaches, we first constructed the genetic network underlying normal myeloid differentiation. In this network, multiple transcriptional regulatory cascades converge on Rora,
indicating a novel function in modulating myeloid development. Next, using expression data in APL, we identified a set
of dysregulated TFs and predicted their aberrantly expressed
targets. These dysregulated TFs formed a genetic pathway
distinct from the normal network that converged on Rxra and
interacted with the normal network through Fos. Finally, we
identified a set of direct targets for PML-RARα and proposed
a role for this set in APL pathogenesis. Together, these results
provide novel insights regarding the genetic circuitry underlying myeloid differentiation and APL pathophysiology, and
our analytical approach demonstrates the utility of an integrated strategy for genetic network construction that may be
applied to study other complex diseases in humans.

Genome Biology 2008, 9:R38

http://genomebiology.com/2008/9/2/R38

Genome Biology 2008,

Results
Construction of transcriptional regulatory networks
Our strategy to identify transcriptional regulatory networks
combines two independent, but complementary methods: TF
binding site identification and analysis of gene expression
profiling data (Figure 1). TF binding site analysis is used to
identify genes containing overrepresented binding sites of a
TF, whereas analysis of gene expression profiling data results
in one or more genes that are coherently expressed with a TF.
Our hypothesis is that genes identified using both methods
are more likely to be regulated by a TF than those genes identified by either of the methods alone. Thus, to predict regulatory targets of a TF by sequence analysis, all the TF binding
sites that are conserved in human and mouse were identified,
and binding probability scores of each TF binding each gene
were calculated using a regulatory sequence analysis pipeline
[29] (Figure 1a). To identify genes with a statistically significant binding score, the P value for observing a binding score
by chance was calculated by randomizing all the identified TF
binding sites in the genome (Figure 1b). In parallel, gene
expression profiles were obtained from cultured bone marrow cells that are stimulated with the granulocyte colonystimulating factor (G-CSF) growth factor to simulate the in
vivo myeloid differentiation program [30]. This system
allowed us to identify important genes that are upregulated
during myeloid differentiation. Template matching was used
to identify genes whose expression is similar to a specific
expression pattern or 'template'. This step identified six coexpressed gene clusters (Figure 1c). The regulatory interactions
identified by sequence analysis were used to construct regulatory networks for each cluster, which were then consolidated
to establish the regulatory network underlying myeloid differentiation (Figure 1d). Each of these steps is described in
greater detail in the following sections.

Transcription factor target identification by regulatory
sequence analysis
To identify regulatory targets of TFs using genomic sequence
information, all of the evolutionarily conserved TF binding
sites in the human genome were identified using 596 known
TF binding profiles curated in the TRANSFAC [31] and JASPAR [32] databases. Using TF binding sites found in the noncoding sequence of a gene, binding probability scores [29],
which assess the likelihood of a TF regulating a gene, were
calculated for each TF-gene pair (Figure 1a). The P value for
observing a binding score for a TF-gene pair by chance was
then calculated by permutation of all the binding sites in the
genome (Figure 1b). By applying a P value cutoff, genes that
have statistically significant binding scores for a TF were
identified as putative targets of that TF. The appropriate P
value cutoff was determined empirically to be 0.005 by using
the total number of transcriptional regulatory interactions
estimated in a previous study [15]. As a result, 106,997 TFtarget gene pairs (that is, a TF regulating a target gene),
including 6,474 TF-target TF pairs (that is, a TF regulating
another TF gene) were identified. Using human-mouse
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ortholog gene pairs calculated using the HomoloGene database (see Materials and methods), these transcriptional regulatory interactions predicted in human were mapped to
orthologs in mouse and thus generated 102,346 TF-target
gene pairs. To determine if these regulatory relationships
were supported by other computational prediction methods,
these results were compared to the data curated in PReMod,
a database of genome-wide cis-regulatory module predictions
[33]. As a result, 40.3% of these TF-target pairs were also predicted in PReMod.

Identification of upregulated gene clusters during
myeloid differentiation
To elucidate the transcriptional regulatory networks underlying myeloid development, expression profiling data were utilized from a previous study that employed a well
characterized model of in vitro myeloid differentiation [30].
In this model, G-CSF is used to stimulate the maturation of
enriched myeloid progenitors. During the seven-day time
course, the predominant cells in culture at days 2 and 3, at
days 4 and 5, and at days 6 and 7 are promyelocytes, midmyeloid cells, and terminally differentiated myeloid cells,
respectively (Figure 2a). Using these data, we identified
coherently expressed genes during myeloid differentiation.
Because myeloid development is a unidirectional, progressive
event, it was hypothesized that genes regulated during this
process have relatively simple expression patterns (that is,
up-regulated or down-regulated at one or more points during
myeloid development). In fact, comparing gene expression
profiles during the in vitro system to an exhaustive list of temporal patterns revealed that the majority of genes that were
triggered at some point in the seven-day time course were upregulated either on just one day or over two consecutive days
(Additional data file 1). Therefore, we focused on these two
types of expression patterns. Expression patterns that were
upregulated on just one day (day 0 to day 7) or over two consecutive days (days 0 and 1 to days 6 and 7) during the myeloid development were defined as 'templates'. The Pearson's
correlation coefficient was calculated for each gene expression profile and template. To focus on the transcriptional regulation of the most coherently expressed genes, a correlation
coefficient cutoff of 0.9 was used to identify genes whose
expression profiles match each template. Using this method,
six coexpressed gene clusters were identified, including genes
upregulated on day 0, 1, 2, or 7, and genes upregulated on
days 0 and 1 or days 6 and 7 (Figure 2b; Additional data file
2). The clusters that were upregulated on day 0, on days 0 and
1, and on days 6 and 7 include the most genes (267, 138, and
118 genes, respectively). These clusters contain many well
known genes that are associated with myeloid differentiation,
including those encoding myeloid differentiation antigens
(for example, Cd2, Cd3d, Cd5), and terminal myeloid differentiation genes (for example, Mmp9, Fpr1, and Itgam).
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Figure 1 of genetic networks construction
Workflow
Workflow of genetic networks construction. This workflow contains four major stages. (a) TF binding site identification. Genomic sequences of annotated
genes are retrieved and aligned, and conserved TF binding sites in genomic sequences are identified. Binding probability scores are calculated using the
identified binding sites. (b) TF target identification. The P value for observing a given binding probability score or higher by chance is calculated using
permutation of TF binding sites. Using a P value cutoff, regulatory targets of each TF are identified. (c) Coexpressed gene cluster identification. Gene
expression profiles are collected from experiments. Coherently expressed genes are identified and clustered. (d) Network construction. Genetic
networks are identified for each coexpressed gene cluster using the target genes predicted for each TF within each gene cluster. The complete regulatory
network is then constructed by consolidating individual networks. Hs, Homo sapiens; Mm, Mus musculus.

Integration of sequence analysis and expression
profiling to construct genetic networks
The results of genomic sequence analysis and expression profiling analysis were integrated to construct the genetic network associated with each coexpressed gene cluster. The
regulatory targets of myeloid TFs were identified by the intersection of genes found in the same cluster with a TF (that is,
those having a similar expression pattern to that of the TF)
and genes having statistically significant binding scores with
that TF. Using this approach, 96 and 25 TF-target gene pairs
were identified for the gene clusters upregulated on day 0 and
days 0 and 1, respectively (Additional data file 3). Note that
there were also genes that were down-regulated on days 0 and

1 and days 6 and 7 (Additional data file 4), but none of the TFs
that were up-regulated at those time points and that had a
known binding profile were predicted as a regulator of these
genes. Thus, these genes may be regulated by other myeloid
TFs whose binding profiles are not yet available. Using the
entire set of predicted TF-target gene pairs, a genetic network
was constructed for each gene cluster (Additional data file 5).
In these networks, TFs and their target genes are represented
by nodes, and a directed edge is drawn from a TF to a gene if
the TF regulates the gene. The identified genetic networks
allowed for the identification of previously unknown TFs that
regulate myeloid differentiation as well as regulatory target
genes of known myeloid regulators. For example, Egr1 was
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Figure 2
Coexpressed
gene clusters identified during myeloid development
Coexpressed gene clusters identified during myeloid development. (a) The predominant cells in culture during the seven-day myeloid differentiation time
course are promyelocytes, mid-myeloid cells, and terminally differentiated myeloid cells cultured at days 2 and 3, days 4 and 5, and days 6 and 7,
respectively. (b) Coherently expressed gene clusters were identified for genes upregulated on just one day (UP0, UP1, UP2 and UP7) or over two
consecutive days (UP01 and UP67) during in vitro myeloid differentiation.

shown to be a candidate myeloid regulator by previous studies [34-36]. However, what myeloid genes are directly
regulated by Egr1 is unclear. Using our results, seven genes
were found to be potentially regulated by Egr1, including
three genes encoding TFs (Figure 3a). Among these genes,
Dusp5 and Egr1 are both strongly upregulated after interleukin-5 treatment in eosinophils [37]. Lmna modulates cellular responses to the transforming growth factor-beta 1
(Tgfb1) signaling pathway [38], and Tgfb1 is regulated by
Egr1 [39]. Further computational analysis showed that all of
these genes have evolutionarily conserved Egr1 binding sites
in their proximal promoter region (Figure 3b). These results
suggest that the regulatory networks constructed by our
method identified potential target genes of Egr1.

Expanding genetic networks by additional myeloid
transcription factors
The previous analysis identified myeloid TFs that are coherently expressed with their target genes during myeloid differentiation. However, there may be additional myeloid TFs that
may not share a similar expression profile with their target
genes (for example, myeloid TFs that are constantly
expressed). The TF binding site analysis described above
identifies TFs that regulate individual genes in the coexpressed gene clusters. Thus, PAP [29] was utilized to identify
additional myeloid TFs that regulate a set of genes in myeloid
gene clusters. PAP scores each TF and predicts TFs that regulate a set of coexpressed genes using a statistical model that is
based on TF binding sites and that is used to calculate a P
value to assess the statistical significance of this binding (see
Materials and methods). Using a P value cutoff of 0.05, up to
five additional TFs were identified for each of the coherently
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Figure 3 regulatory targets of Egr1 in myeloid differentiation
Predicted
Predicted regulatory targets of Egr1 in myeloid differentiation. (a) Seven genes were identified as direct regulatory targets of Egr1. Three of these genes
encode TFs (circle nodes). (b) Evolutionarily conserved Egr1 binding sites (red bars) were identified in the ± 2 kb proximal promoter region of the
predicted target genes. All the Egr1 binding sites were conserved in human, mouse and rat except for PRDM16, whose rat ortholog was not available.
Gene annotation information is color coded: blue, repetitive elements; yellow, conserved sequence; dark green, coding region; light green, untranslated
region.

expressed gene clusters (Table 1). A majority of these additional TFs are known myeloid regulators or are involved in
leukemia pathophysiology, including AML1, PU.1, and C/
EBPα. These TFs were added into the genetic network for
each gene cluster as new nodes (Additional data file 6), and
connections from these TFs to other genes in each individual
network were made based on the TF-target gene pairs predicted by genomic sequence analysis (Additional data file 7).

Myeloid genetic networks among transcription factor
genes
To systematically study the transcriptional regulatory mechanisms underlying myeloid differentiation, focus was given to
TF genes in each coexpressed gene cluster. These TFs presumably modulate myeloid development by regulating the
genes in the same gene cluster (that is, genes that were coexpressed with the TFs). Indeed, 12 of the 17 TFs found in these
gene clusters were previously associated with myeloid differentiation or myeloid disorders (Table 2). Therefore, the regulatory networks of TFs were extracted from each genetic
network identified for each gene cluster (Additional data file
8). Because genes in each coexpressed cluster are upregulated
at different time points during myeloid development, each
individual network represents a 'sub-network' of the entire
transcriptional regulatory network for myeloid differentiation. Therefore, a comprehensive transcriptional regulatory
network was constructed by combining each individual net-

work identified in each coexpressed gene cluster. Namely,
each individual network was joined by the common TFs to
build a combined network (Figure 4a).
The identified genetic network for myeloid differentiation has
several interesting features. First, the integration of individual networks into the complete myeloid development network was consistent with the time at which each individual
gene cluster was upregulated (that is, genes upregulated earlier occupied the upper part of the network and genes upregulated later occupied the lower part). Second, multiple
regulatory pathways converge on a single TF, Rora. These
characteristics highlight the genetic circuitry that may be
operating in the myeloid differentiation.

Genetic networks in acute promyelocytic leukemia
To identify transcriptional regulatory mechanisms that are
dysregulated in acute promyelocytic leukemia, TFs that are
differentially expressed in APL compared to normal cells
were identified as follows. Gene expression profiles in APL
were collected from a mCG-PML-RARα knock-in mouse
model [30]. PML-RARα is a fusion protein observed in most
APL patients, and the majority of PML-RARα knock-in mice
eventually develop APL [30]. Because APL is characterized by
an arrest of the normal myeloid differentiation program in
the promyelocytic stage, and promyelocytes are the predominant cells at day 2 and day 3 of the in vitro myeloid matura-
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Table 1
Additional myeloid transcription factors identified by PAP

Cluster

Accession

TF

Symbol

Association with myeloid development

UP0

Reference

MA0081

SPI-B

Spib

Can functionally replace PU.1 in myeloid development

[85]

M00961

VDR

Vdr

Involved in monocytic differentiation in human leukemia cells

[86]

M00777

STAT

Stat4

Expressed in early myeloid development

[79]

MA0103

deltaEF1

Zfhz1a

M00655

PEA3

Etv4

UP1

M00161

Oct-1

Pou2f1

Regulates PU.1

[87]

UP7

M00658

PU.1

Sfpi1

Known regulator of hematopoiesis

[88]

Known regulator of myeloid development

[89]

UP01

UP67

M00329

Pax-9

Pax9

M00925

AP-1

Jun

M01031

HNF4

Hnf4a

MA0081

SPI-B

Spib

Can functionally replace PU.1 in myeloid development

[85]

M00217

USF

Usf1

Regulates HOXB4 in normal and leukemia stem cells

[90]

M00792

SMAD

Smad1

M00805

LEF1

Lef1

Expression altered in acute leukemia

[77]

M00799

Myc

Myc

Upregulated in AML and induces AML

[91]

MA0002

AML-1

Runx1

Known regulator of hematopoiesis

[88]

M00133

Tst-1

Pou3f1
[89]

M00188

AP-1

Jun

Known regulator of myeloid development

M00729

Cdx-2

Cdx2

Involved in the ETV6-CDX2 fusion protein

[92]

M00912

C/EBP

Cebpa

Known regulator of hematopoiesis

[88]

M00162

Oct-1

Pou2f1

Regulates PU.1

[87]

PAP was used to identify overrepresented TF binding sites in each coexpressed gene clusrer. Almost all of these TFs are associated with myeloid
development or myeloid leukemia.

tion program, gene expression data measured at these two
days were compared to those measured in APL mice. The
software program SAM (Significance Analysis of Microarrays) [40] was used to identify 602 differentially expressed
genes in APL. Among these genes, 472 were overexpressed in
APL, and 130 were underexpressed. These differentially
expressed genes include seven encoding TFs (Stat5b, Fos,
Atf1, Arid5b, Rxra, Mybl2, Nfyc) that have characterized
binding profiles, termed the APL dysregulome (Table 3). Four
of the seven dysregulated TFs, Atf1, Fos, Rxra and Stat5b,
have been previously associated with acute myeloid leukemia
[41-44], and ninety-six genes that were differentially
expressed in APL were identified as targets of these TFs
(Additional data file 9).
To test if these seven TFs in the APL dysregulome participate
in a common regulatory pathway (that is, their abnormal
expression is the cause or result of a single regulatory
cascade), transcriptional regulatory interactions between
these TFs were identified using regulatory sequence analysis
(see above and Materials and methods). Namely, TF-A and
TF-B are connected to form a regulatory pathway if TF-B has
over-represented binding sites of TF-A. As a result, six of
these seven TFs were shown to form a common regulatory
pathway (Figure 4b). The last TF, Nfyc, neither regulates nor
is regulated by any of the other six TFs, but it regulates a gene

(Actl6a) in common with Atf1. Two of these seven TFs, Nfyc
and Mybl2, are expressed at lower levels in APL than in normal promyelocytes. It is interesting to note that while Atf1
regulates Fos and Actl6a, Fos is up-regulated and Actl6a is
down-regulated in APL. This suggests that Atf1 may act as
both a transcriptional activator and a repressor, possibly
depending on different cooperative factors. This hypothesis is
supported by a previous study of Atf1 [45]. Thus, to identify
cooperative TFs of Atf1, TFs that regulate Fos or Actl6a and
have similar expression profiles to Atf1 in APL were identified. This analysis identified Egr2 and Nfyb as cofactors of
Atf1 in the regulation of Fos and Actl6a, respectively.
To study how the APL dysregulome perturbs the genetic network of normal myeloid differentiation, the regulatory cascade of the seven dysregulated TFs were joined with the
normal myeloid genetic network (Figure 4c). All the predicted
regulatory interactions between any two TFs within the normal genetic network were maintained, and the TFs that were
predicted as targets of at least one dysregulated TF were identified (Table 4, Figure 4c). Interestingly, these two networks
could be simply combined through a common TF, Fos. This
result suggests that the genetic network of normal myeloid
differentiation is perturbed, and this dysregulation is mediated through Fos. Furthermore, these results predict a change
in the genetic circuitry wherein the normal cascade is regu-
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Figure 4networks operating in myeloid development and APL
Genetic
Genetic networks operating in myeloid development and APL. In these networks, circle nodes represent TF genes. Genes that do not encode TFs are
shown in rectangles. An arrow is drawn from TF-A to gene-B if TF-A regulates gene-B. (a) The predicted genetic network operating in myeloid
differentiation. Multiple regulatory pathways in this network converge on one single TF, Rora. The expression profiles of the TF genes are color coded:
blue, upregulated at day 0; yellow, upregulated at day 0 and day 1; purple, upregulated at day 7. (b) The seven TFs that are dysregulated in APL may be
connected to form a common regulatory pathway. Aberrant expressions of these TFs are color coded: red, overexpression; green, underexpression. (c)
The perturbation of the normal network by dysregulated TFs in APL. The normal and disease regulatory pathways converge on Rora and Rxra,
respectively. The dysregulated pathway in APL may perturb the normal genetic network through Fos. Furthermore, many TFs in the normal network
(shown in orange nodes) are predicted as direct targets of at least one TF dysregulated in APL (Table 4).

lated by Rora while the pathophysiology observed in APL is
mediated by Rxra. Bona fide downstream targets of Rora and
Rxra need to be identified, and their functions in normal myeloid development or APL need to be elucidated to further validate the role of Rora and Rxra in normal or leukemic biology.

PML-RARα and APL pathogenesis
While the proposed genetic network predicted that the APL
pathway converged on Rxra, the relationship between PMLRARα and the APL dysregulome was not uncovered. Thus, to
test whether the APL dysregulome (Figure 4b) is caused
either directly or indirectly by PML-RARα, PML-RARα TF
targets were identified using RARα binding profiles. Because
it has been shown that PML-RARα binds to a much broader
range of binding site architectures than the normal RARα,
eight binding profiles of PML-RARα with various orientations and spacings (DR2, DR3, DR4, DR5, DR6, DR12, IR0,
and ER8) were created based on a previous experimental
study [46] in addition to the RARα binding profiles in
TRANSFAC. Using the same binding site permutation
algorithm, none of the TFs in the APL dysregulome were predicted as direct targets of PML-RARα, suggesting that dysregulation of these TFs was mediated by other TFs.

derived from young mCG-PML-RARα knock-in mice were
used (see Materials and methods). First, to identify genes dysregulated in preleukemic promyelocytes, expression data
from days 0, 2, and 7 in normal and preleukemic
promyelocytes were analyzed using SAM. No genes were differentially expressed at day 0, whereas 73 and 1,028 genes
were differentially expressed at day 2 and day 7, respectively.
Using the eight binding profiles of PML-RARα and the RARα
binding profiles in TRANSFAC, six TFs differentially
expressed at day 7 were predicted as direct PML-RARα targets (Table 5). Interestingly, one of the TFs in the normal network, Egr1, is also predicted as a PML-RARα target; however,
Egr1 is expressed at a normal level in young, preleukemic
mice. Therefore, it is possible that Egr1 may not be a direct
mediator of PML-RARα in leukemogenesis. Collectively,
these results suggest a model of APL pathogenesis in which
PML-RARα regulates the APL dysregulome through six
mediator TFs. This circuitry ultimately converges to create
the APL dysregulome, hallmarked by activation of Rxra,
which then triggers downstream events (Figure 5).

Discussion
A novel approach to genetic network identification

Thus, to identify direct targets of PML-RARα, gene expression profiles collected from cultured bone marrow cells

In this report, we propose a novel approach to genetic network identification that combines two independent types of
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Table 2
Transcription factor genes identified in coexpressed gene clusters

Cluster

Gene ID

UP0

13653
13654
14013

Evi1

14281

Fos

16842

UP01

UP67

Symbol

Expression correlation coefficient

Association with myeloid development

Reference

Egr1

0.9928

Stimulates development of hematopoietic progenitor cells

[35]

Egr2

0.9459
0.9373

Involved in many myeloid disorders

[76]

0.9488

Modulates myeloid cell survival and differentiation

[42]

Lef1

0.9325

Expression altered in acute leukemia

[77]

17131

Smad7

0.9041

Alters cell fate decisions of human hematopoietic repopulating cells

[78]

18109

Mycn

0.9094

19883

Rora

0.9335

20849

Stat4

0.9562

Expressed in early myeloid development

[79]

21414

Tcf7

0.9614

56458

Foxo1

0.9575

Activates the mixed lineage leukemia gene

[80]
[76]

14013

Evi1

0.9042

Involved in many myeloid disorders

14391

Gabpb1

0.9377

Activates the neutrophil elastase promoter

[81]

16842

Lef1

0.9593

Expression altered in acute leukemia

[77]

18044

Nfya

0.9036

18109

Mycn

0.9509

19883

Rora

0.9525

217082

Hlf

0.9537

E2A-HLF fusion abrogates apoptosis in leukemia cells

[82]

12013

Bach1

0.9274

17119

Mxd1

0.9168

Expression induced during myeloid development

[83]

328572

Ep300

0.9097

Regulates Runx1 through acetylation of lysine residues

[84]

These TFs were all upregulated on just one day or over two consecutive days during the seven-day in vitro myeloid differentiation. Twelve of these
seventeen TF genes aare known to regulate myeloid differentiation or be involved in myeloid leukemia.

information, gene expression profiling data and computational identification of TF binding sites. Using gene expression data, genes coherently expressed with TFs were first
identified. In parallel, direct regulatory targets of TFs were
predicted by a computational model that calculates binding
scores for each coexpressed gene and assesses statistical significance using binding site permutation. These two types of
information were then integrated to construct the genetic network for each coexpressed gene cluster, which were subsequently consolidated into a comprehensive network. We used
this approach to identify the genetic network in normal myeloid differentiation and to determine how this network is
perturbed in APL. This approach is general and may be
applied to delineate genetic networks operating in other complex human diseases.

cific set of reference sequences. Instead, the binding scores of
genes in the entire genome are calculated, and the P value for
observing a score is determined by permutation of all the
binding sites. Secondly, unlike most previous methods where
TF binding sites are only identified in the proximal promoter
region, our model considers binding sites located in evolutionarily conserved sequences in the entire gene locus. This
includes a significant number of additional, highly conserved
sites found in introns and distant genomic regions. These
modifications and improvements make our predictions more
accurate due to a better scoring model and more
comprehensive due to a more complete set of evolutionarily
conserved TF binding sites [47].

Prediction of direct regulatory targets using TF binding
site identification

In this study, we used an in vitro, G-SCF driven myeloid differentiation system to model normal myeloid maturation and
compared its gene expression profile to that of an in vivo APL
mouse model. Although the in vitro GCS-F driven myeloid
differentiation is not equivalent to in vivo differentiation, it is
a validated surrogate that mimics human myeloid differentiation [30]. Moreover, this system is currently the only practical and technically feasible platform for the study of normal
murine myeloid development. Therefore, we believe the data

A major challenge in expression data-based genetic network
construction is the ability to distinguish direct regulatory targets of TFs from indirectly regulated downstream genes. To
predict direct targets accurately, coexpressed genes were
scored using the identified TF binding sites, and the statistical
significance of each score was determined. This method is different from other existing approaches in several ways. First, it
does not compare the frequency of TF binding sites to a spe-

Using the in vitro cell culture system to model human
myeloid differentiation
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Table 3
Dysregulated transcription factors in APL

Gene ID

Symbol

Gene name

APL expression

SAM score

20851

Stat5b

14281

Fos

signal transducer and activator of transcription 5B

Up

12.05

FBJ osteosarcoma oncogene

Up

9.71

11908
71371

Atf1

activating transcription factor 1

Up

9.68

Arid5b

AT rich interactive domain 5B (Mrf1 like)

Up

9.63

20181

Rxra

retinoid X receptor alpha

Up

9.48

17865

Mybl2

myeloblastosis oncogene-like 2

Down

-9.47

18046

Nfyc

nuclear transcription factor-Y gamma

Down

-10.21

SAM was used to identify seven TFs that are differentially expressed in APL and in normal promyelocytes. Five of these TFs are upregulated in APL,
while two of them are downregulated.

provided by this system can be used to infer hematopoietic
gene regulation.

Comparing the identified genetic networks with
previous experimental data
The genetic network of TFs identified by our computational
method provides several new insights into the normal and
aberrant regulatory pathways that may drive myeloid differentiation and in acute promyelocytic leukemia, respectively.
These predictions are compared to several previous findings.
First, we observed that the normal and disease regulatory cascades converge on Rora and Rxra, respectively. Rora and
Rxra belong to the same family of nuclear receptors and are
related to Rara, and Rxra forms a heterodimer with Rara.
Although the specific functions of Rora in myeloid differentiation are still unknown, all three nuclear receptors bind to
very similar DNA sequences ((A/G)GGTCA) [46,48], imply-

ing that they may regulate the same genes. In addition, the
human RORA gene is located within a highly conserved
region on chromosome 15 near the human PML gene [49].
Therefore, our results suggest a novel role for Rora in myeloid
development. Furthermore, the dysregulated pathway in APL
leads to an overexpression of Rxra, and the absence of Rxra in
the normal network implies that Rxra is a potential effector
protein in APL but not in normal myeloid development. In
fact, recent studies have shown that although Rxra is not
required in normal myelopoiesis [50], it is an essential component for the PML-RARα complex to initiate APL in mice
[51,52]. Therefore, the prediction of Rxra as a potential key
participant in APL pathogenesis is supported by in vivo studies.
Second, the normal and the disease pathways did not share
many common TFs. Instead, only one TF in the normal network, Fos, which modulates myeloid cell survival and differ-

Table 4
Transcription factors in the normal myeloid genetic network regulated by dysregulated transcription factors in APL

Differentially expressed TFs in APL

Regulated TFs in normal myeloid development

P value

Arid5b

Rora

~0

Arid5b

Tcf7

0.0019

Atf1

Egr1

Atf1

Hlf

0.0041

~0

Atf1

Rora

0.0015

Atf1

Smad7

0.0015

Fos

Egr2

0.0005

Fos

Rora

~0

Fos

Tcf7

0.0036

Fos

Zfhx1a

0.0005

Mybl2

Rora

~0

Rxra

Egr1

0.0003

Rxra

Etv4

0.0014

Stat5b

Foxo1

0.0005

These regulatory targets were identified using permutation of TF binding sites.
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expression of Fos in APL may have an aberrant activation
function as well. This over-expression of Fos may be induced
by PML-RARα and may, in turn, cause the dysregulation of
other TFs involved in APL.

PMLRARa

Egr2

Volume 9, Issue 2, Article R38

Runx1
Nfya

Figure
The
proposed
5
model of APL pathogenesis induced by PML-RARα
The proposed model of APL pathogenesis induced by PML-RARα. PMLRARα may activate the dysregulation of several TFs in the disease
regulatory pathway in APL through six mediator TFs (dashed blue arrow).
This regulatory circuitry ultimately converges on the overexpression of
Rxra. Red circle, overexpressed TFs; green circle, underexpressed TFs;
green box, underexpressed genes; orange circle, TFs in the normal
network that are predicted as targets of dysregulated TFs in APL; gray
circle, other TFs in the normal network; purple circle, PML-RARα.

Third, we identified a set of six TFs as direct targets of PMLRARα. Among these six TFs, five of them were overexpressed
in APL, and one TF was underexpressed, suggesting PMLRARα may act as both a repressor and an activator. In agreement with this observation, PML-RARα was first demonstrated as an enhanced repressor of retinoic acid target genes
by its stronger binding to corepressors than wild-type RARα
[55,56], but it is becoming clear that PML-RARα may also
function as an activator [54,57]. While a version of PMLRARα that can only repress gene expression is still
leukemogenic [58], whether PML-RARα can trigger APL
pathogenesis by gene activation is unknown. Our analysis
suggests that PML-RARα may indeed be an activator and provides a potential mechanism through which this may occur.
Finally, our data are consistent with a previous study that
showed that relative levels of Sfpi1 regulate macrophage versus neutrophil differentiation [59]. Importantly, at low Sfpi1
levels (neutrophil differentiation), we did not find that Egr1/
2 are targets of Sfpi1 whereas Laslo et al. [59] found that
Egr1/2 are targets of Sfpi1 during macrophage differentiation
where Sfpi1 is expressed at high levels. Therefore, there may
be weaker binding sites for Sfpi1 in Egr1 or Egr2 promoters,
and thus the activation of Egr1 and Egr2 may require a higher
expression level of Sfpi1.

Genetic networks may be expanded using additional
information on binding profiles
entiation [42], was dysregulated in APL. Our analysis
identified that the TFs dysregulated in APL may mediate the
perturbation of the normal myeloid genetic network through
Fos. Indeed, previous studies have demonstrated that PMLRARα promotes cell growth by activating Fos [53], and that
PML-RARα directly functions as a co-repressor of Fos in the
absence of retinoic acid [54]. Our data suggest that over-

The computational approach used in this study is based on
the binding profiles of TFs in TRANSFAC and JASPAR.
Therefore, the quality of our prediction and the accuracy of
our conclusions may be dependent upon the quality of the
binding models in these databases. Some TFs require other
co-factors to accomplish their regulatory functions, and so
their binding specificities or preferences may also be depend-

Table 5
Predicted mediator transcription factors of PML-RARα

Gene ID

Symbol

Gene name

APL expression

SAM score

12053

Bcl6

B-cell leukemia/lymphoma 6

Down

-7.39

21429

Ubtf

upstream binding transcription factor, RNA polymerase I

Up

4.49

56070

Tcerg1

transcription elongation regulator 1 (CA150)

Up

6.25

56463

Snd1

expressed sequence AL033314

Up

4.44

71458

Bcor

Bcl6 interacting corepressor

Up

4.90

109151

Chd9

chromodomain helicase DNA binding protein 9

Up

5.64

SAM and the binding profiles of Rara and PML-RARα were used to identify direct regulatory targets of PML-RARα. These six TFs may activate the
dysregulation of other aberrantly expressed TFs in APL.
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ent on their binding partners. Such information may not have
been included in the TRANSFAC or JASPAR models. For
example, the TF RXRA studied in this work typically forms a
heterodimer with various co-factors, including RAR, VDR,
TR, or PPAR at various spacings. The four binding profiles we
used were created using different binding partners of RXRA,
including PPAR (M00518), RAR and TR (M00963), and VDR
(M00966). Thus, our prediction did consider the binding site
of RXRA with different binding partners. However, our prediction may not include all the allowable spacings between
the two sites. Therefore, our results may be further improved
when more precise and complete binding profiles are
available.
While the direct targets of PML-RARα in APL were computationally identified, the direct targets of these mediator TFs
could not be determined. Therefore, the genetic network in
APL was not fully elucidated (Figure 5). In order to identify
targets of these mediator TFs, knowledge of their binding
profiles is required, information that is currently not
available. In fact, while there are more than 2,000 TFs predicted in the human genome [60], only a quarter of them have
known binding profiles. Thus, the predicted genetic network
may be further improved and expanded when more TF binding profiles become available. Additional TF binding profiles
may be generated by traditional protein-DNA binding assays
[61] or by computational approaches that utilize evolutionary
conservation of functional sequences. This latter approach is
used to predict DNA binding profiles on a genome-wide scale.
For example, DNA binding patterns may be identified by calculating the conservation rate of a given oligonucleotide
across the genome [62], or by clustering genes that share
common conserved sequences [63]. Thus, the employment of
such methods is a rational next step toward the refinement of
genetic networks. Integration of this computational component would not only increase our understanding of the molecular mechanisms underlying APL but would also facilitate the
construction of more comprehensive regulatory networks
driving other complex diseases.

Conclusion

We have developed an integrated approach to mammalian
genetic network construction by combining gene expression
profiling data and TF binding site identification. Using this
technique, we have predicted Rxra as a key regulator in APL
and Fos as one of the key mediators of PML-RARα. These
results provide new insights about the pathophysiology of
APL. Our approach may be applied to study the genetic circuitry operating in other complex diseases in humans.
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Materials and methods
Genomic sequence collection and ortholog
identification
The genomic sequences of human, mouse, and rat were
acquired from the NCBI's Genome Assembly Project [64].
Genome build 35 was used for human, build 33 for mouse and
build 3 for rat. The genomic sequence of a gene locus was
defined as the sequence between the end of the upstream
gene and the end of the gene itself. Within this range, protein
coding sequences were masked and excluded from the search
of TF binding sites. Repetitive elements were also masked by
the program RepeatMasker [65] using slow and sensitive
mode (the -s flag). Human, mouse and rat ortholog gene
groups (13,194 in total) were identified using the annotation
of NCBI's HomoloGene database as previously described
[29]. Genomic sequences of the genes in the same ortholog
group were then aligned using the program TBA [66].

TF binding site identification and binding probability
score calculation
To identify TF binding sites, 596 vertebrate TF binding profiles were collected from the TRANSFAC (version 9.1) and
JASPAR databases. The program PATSER [67] was used to
search for matches of these profiles in the genome using
default cutoff scores (the -li option). This cutoff score is
calculated as follows: for each position, PATSER scores the
subsequence and calculatesthe P value for observing the same
score or higher at thatposition [68]. A P value cutoff is calculated for each binding profile using its information content.
The score corresponding to that P value cutoff is then chosen
to be the cutoff score. After all the TF binding sites were identified, binding probability scores [29] for each TF-gene pair
were then calculated using evolutionarily conserved TF binding sites found in the non-coding sequence of a gene. For
mammals, functional regulatory elements have been found in
distant upstream regions [69,70] as well as intronic
sequences [71,72]. However, searching for TF binding sites in
the entire intergenic sequence and in the entire gene locus
frequently results in a high false discovery rate. Therefore, to
overcome this problem, we considered only evolutionarily
conserved TF binding sites in the 'proximal promoter region'
of a gene and in the most conserved sequence regions within
a gene locus defined by multi-species conserved sequences
(MCSs) [73].
The proximal promoter region of a gene was defined as the 10
kb upstream sequence and the 5 kb downstream sequence
from the transcription start site, regardless of the presence of
an upstream gene or a downstream gene. MCSs are defined as
the top 5% conserved sequences in the human genome when
compared to another 11 vertebrate genomes [73]. The human
MCSs were first downloaded, and the MCSs in mouse and rat
were defined by mapping the human MCSs to the mouse or
rat genomes using multiple sequence alignments generated
by TBA. These multiple sequence alignments were also used
to identify evolutionarily conserved TF binding sites, which
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were defined as sites located within conserved sequence
regions, present in all the species and aligned in the multiple
sequence alignment [74].

Calculating statistical significance for a binding
probability score
To predict regulatory targets of TFs, genes that have statistically significant binding scores [29] for a TF were identified.
The statistical significance of a given binding score was evaluated by the P value for observing an equal or higher score by
chance. This P value was calculated by permutation of all the
TF binding sites in the genome. In this algorithm, each individual binding site of a TF was randomly assigned to genes in
the genome based on a precalculated probability distribution
calculated as follows: the probability for a gene to acquire a
given TF site is the length of the TF binding site search range
of that gene (that is, the proximal promoter region and the
MCSs; see above) divided by the sum of the TF binding site
search ranges of all the genes in the genome. This permutation of TF binding sites was performed for 10,000 iterations.
After each iteration, a new binding probability score was calculated for each gene using the TF sites randomly assigned to
that gene. The P value for observing a score for a gene was
then calculated by the number of iterations where a binding
score equal to or higher than the true score was obtained for
that gene, divided by the total number of iterations.

Volume 9, Issue 2, Article R38

Chang et al. R38.13

cluster, PAP ranked all the TFs by their R-scores, which were
calculated based on overrepresentation of their binding sites
in the coexpressed genes. To find TFs that have a statistically
significant R-score, a P value for each R-score was calculated
using 10,000 randomly selected gene clusters of the same
size. For each random set, the R-scores for each TF were calculated, and the P value for a TF was calculated as the number
of gene clusters that had an equal or higher score than that of
the original gene cluster, divided by 10,000, the total number
of random sets.

Abbreviations

AML, acute myeloid leukemia; APL, acute promyelocytic
leukemia; G-CSF, granulocyte colony-stimulating factor;
MCSs, multi-species conserved sequences; SAM, Significance
Analysis of Microarrays; TF, transcription factor.
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Additional data files
Gene expression profiling data
Gene expression profiles in normal myeloid differentiation
were obtained from a G-CSF stimulated in vitro myeloid differentiation model [30]. Expression data were collected from
cultured bone marrow cells in two independent experiments
during a seven-day time course. Gene expression data in APL
were collected from bone marrow cells of six adult PMLRARα knock-in mice based on a previously developed murine
APL model [30]. Expression profiles of the cultured bone
marrow cells were also collected from two sets of young PMLRARα knock-in mice. For the expression data collected from
cultured cells, only probesets that were present on at least one
day in at least one experiment were considered.

Coexpressed gene cluster identification

The following Additional data files are available with the
online version of this paper. Additional data file 1 is a spreadsheet showing the number of genes that were up-regulated at
any number of consecutive days during the in vitro myeloid
development system. Additional data file 2 is a spreadsheet
containing a list of genes identified in each coexpressed gene
cluster. Additional data file 3 is a spreadsheet containing a list
of predicted regulatory targets of TFs identified in each
coexpressed gene cluster. Additional data file 4 is a
spreadsheet containing a list of down-regulated genes in the
in vitro myeloid differentiation system. Additional data file 5
is a PDF file showing the complete genetic networks (including genes that do not encode TFs) for genes upregulated at
day 0, and at day 0 and day 1. Additional data file 6 is a PDF
file showing the expanded genetic networks (including additional TFs identified by PAP) for genes upregulated at day 0,
and at day 0 and day 1. Additional data file 7 is a spreadsheet
containing a list of myeloid TFs identified by PAP and their
regulatory relationships to other genes in the myeloid development networks. Additional data file 8 is a PDF file showing
regulatory networks for TF genes identified in each coexpressed gene cluster. Additional data file 9 is a spreadsheet
containing a list of TFs dysregulated in APL and their predicted regulatory targets.

The coexpressed gene clusters during myeloid differentiation
were identified using the template matching clustering tool in
the software suite FunctionExpress [75]. The templates for
each upregulated expression pattern were created manually,
including genes that were upregulated on just one day or over
two consecutive days during the seven day time course. The
Pearson's correlation coefficient was used to quantify the similarity between the template and the expression profile of
each probeset. A cutoff of 0.9 was applied to the correlation
coefficient to identify the coexpressed gene clusters.
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